Work Package 3 | Starting and delivery point (months) M4-M36

ncRNA diagnostics

leader
partners

Objective WP3

This WP will analyse a specific set of 50 ageing/HF-associated circulating ncRNAs. This set will be derived from WP1 & WP2, comprehensive literature searches, mining of databases (e.g. gene expression omnibus) and from unpublished findings of consortium members.

Available to EXPERT are various healthy and diseased human cohorts complete with plasma/serum samples for ncRNA measurements and existing data on ageing characteristics, diverse relevant CVD-related clinical events and relevant co-morbidities and confounders.

The overall aim of WP3 is to generate and test a small, well-defined panel of age-related ncRNAs in available large clinical and population-based cohorts (n >10,000 individuals and >50,000 patient years of follow up, see table below).

Cohorts Name
n of subjects w/ available samples
Mean Age (y)
Male (%)
Cardiac disease
Follow-up (FU)
Type of samples available
STANISLAS
>4000 @V1
≥1600 @V4
27±14
49±14
50
48
Natural age-associated CVD
Every 5-y after enrolment
Total of 18-y FU (@V4)
V4: 250μl serum
250μl plasma. V1-V3 smaller volumes
EPHESUS
451 @ V1
62±11
76
Post-MI
Up to 15 months
250μl serum or 250μl plasma
REMI
111
56±9
89
Post-MI
6 months
250μl serum or 250μl plasma
AURORA
2,776
64±8
60
End stage renal disease
>48 months
250μl serum or 250μl plasma
ALCHEMIST
800
on-going
on-going
End stage renal disease
>48 months
250μl serum or 250μl plasma
Hannover HCM
>110 (recruiting)
on-going
on-going
Hypertrophic cardiomyopathy
3 years
250μl serum or 250μl plasma
PESA
4066
45.8±4.3
63
No (CVD-Free)
Every 3-y after enrolment. Total of 6-y FU (@V3)
250μl serum